| 81.91 Delayed Data As of Aug 23 |  -3.65 / -4.27%Today’s Change | 57.00 Today|||52-Week Range 89.30 | +28.81% Year-to-Date |
| Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer Aug 19 / Zacks.com - Paid Partner Content | How Big Is Celgene's Latest Good News? Aug 18 / MotleyFool.com - Paid Partner Content |
| Previous close | 85.56 |
| Today’s open | 85.56 |
| Day’s range | 81.58 - 85.82 |
| Volume | 1,213,363 |
| Average volume (3 months) | 1,244,238 |
| Market cap | $17.9B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +217.80% |
| Earnings growth (next 5 years) | +41.50% |
| Revenue growth (last year) | +22.50% |
| P/E ratio | 57.7 |
| Price/Sales | 7.29 |
| Price/Book | 9.20 |
| Today’s change | Today’s % change | |
|---|---|---|
| SGENSeattle Genetics Inc | -2.07 | -2.64% |
| IONSIonis Pharmaceutical... | +0.11 | +0.16% |
| MYLMylan NV | -0.70 | -3.68% |
| ALXNAlexion Pharmaceutic... | -8.16 | -6.61% |
| Next reporting date | October 30, 2019 |
| EPS forecast (this quarter) | $0.40 |
| Annual revenue (last year) | $1.9B |
| Annual profit (last year) | $109.5M |
| Net profit margin | 5.82% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Hervé Hoppenot |
Chief Financial Officer & Executive Vice President Christiana Stamoulis |
Corporate headquarters Wilmington, Delaware |
